

1 **Evaluation of a Rapid and Accessible RT-qPCR Approach for SARS-CoV-2 Variant of Concern**

2 **Identification**

3  
4 Priscilla S.-W. Yeung, MD, PhD<sup>a\*</sup>; Hannah Wang, MD<sup>a\*</sup>; Mamdouh Sibai, BS<sup>a</sup>; Daniel Solis, BS<sup>a</sup>; Fumiko  
5 Yamamoto, MS<sup>a</sup>; Naomi Iwai, CLS<sup>b</sup>; Becky Jiang, CLS<sup>b</sup>; Nathan Hammond, PhD<sup>c</sup>; Bernadette Truong,  
6 CLS<sup>b</sup>; Selamawit Bihon, CLS<sup>b</sup>; Suzette Santos, CLS<sup>b</sup>; Marilyn Mar, CLS<sup>b</sup>; Claire Mai, BS<sup>c</sup>; Kenji O. Mfuh,  
7 PhD<sup>b</sup>; Jacob A. Miller, MD<sup>d</sup>; ChunHong Huang, MD<sup>a</sup>; Malaya K. Sahoo, PhD<sup>a</sup>; James L. Zehnder, MD<sup>a</sup>;  
8 Benjamin A. Pinsky, MD, PhD<sup>a,b,e,#</sup>

9  
10 <sup>a</sup> Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

11 <sup>b</sup> Clinical Virology Laboratory, Stanford Health Care, Stanford, CA, USA

12 <sup>c</sup> Clinical Genomics Laboratory, Stanford Health Care, Stanford, CA, USA

13 <sup>d</sup> Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA

14 <sup>e</sup> Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University  
15 School of Medicine, Stanford, CA, USA

16

17 Running Head: SARS-CoV-2 Variant of Concern Genotyping

18

19 #Address correspondence to Benjamin A. Pinsky, MD, PhD, [bpinsky@stanford.edu](mailto:bpinsky@stanford.edu)

20

21 \*Authors Priscilla S.-W. Yeung and Hannah Wang contributed equally to this work. Author order was  
22 determined reverse-alphabetically.

23 **ABSTRACT**

24

25 The ability to distinguish between SARS-CoV-2 variants of concern (VOCs) is of ongoing interest due to  
26 differences in transmissibility, response to vaccination, clinical prognosis, and therapy. Although detailed  
27 genetic characterization requires whole-genome sequencing (WGS), targeted nucleic acid amplification  
28 tests can serve a complementary role in clinical settings, as they are more rapid and accessible than  
29 sequencing in most laboratories.

30

31 We designed and analytically validated a two-reaction multiplex reverse transcription quantitative PCR  
32 (RT-qPCR) assay targeting spike protein mutations L452R, E484K, and N501Y in Reaction 1, and del69-  
33 70, K417N, and T478K in Reaction 2. This assay had 95-100% agreement with WGS in 502 upper  
34 respiratory swabs collected between April 26 and August 1, 2021, consisting of 43 Alpha, 2 Beta, 20  
35 Gamma, 378 Delta, and 59 non-VOC infections. Validation in a separate group of 230 WGS-confirmed  
36 Omicron variant samples collected in December 2021 and January 2022 demonstrated 100% agreement.

37

38 This RT-qPCR-based approach can be implemented in clinical laboratories already performing SARS-  
39 CoV-2 nucleic acid amplification tests to assist in local epidemiological surveillance and clinical decision-  
40 making.

41

42 **INTRODUCTION**

43

44 Since the original strain of SARS-CoV-2 virus was first discovered in late 2019, numerous new variants  
45 have been identified, including variants of concern (VOCs) Alpha (B.1.1.7 and sublineages), Beta  
46 (B.1.351), Gamma (P.1 and sublineages), Delta (B.1.617.2 and sublineages) and Omicron (B.1.1.529 and  
47 sublineages) (1). Importantly, these VOCs differ in their clinical prognosis, transmissibility, antibody  
48 susceptibility, and response to vaccination (2-22). Whole-genome sequencing (WGS) has played a critical  
49 role in identifying the emergence of these new variants (23-25), and millions of distinct sequences have  
50 been deposited into public repositories such as the Global Initiative on Sharing Avian Influenza Data  
51 consortium's database (GISAID) (26). However, WGS has a relatively long turnaround time, is labor-  
52 intensive, and requires instruments, bioinformatics support, and specially-trained staff that may not be  
53 widely available to many clinical laboratories. Therefore, the development of reverse transcription  
54 quantitative PCR (RT-qPCR) assays to presumptively type SARS-CoV-2 variants may be an important  
55 real-time complement to WGS epidemiologic surveillance, and may directly impact the clinical care of  
56 individual patients by informing selection of expensive and potentially difficult-to-source monoclonal  
57 antibody therapies (2, 7, 13-17, 20, 21, 27). It is important to note that such presumptive typing assays  
58 may provide atypical results in emerging strains due to mutations within primer and/or probe binding sites.  
59 As such, they must be intelligently-designed, thoroughly validated, and interpreted carefully.

60

61 In this study, we report the design of a multiplex RT-qPCR assay that detects the del69-70, K417N, and  
62 T478K mutations in SARS-CoV-2 spike protein and targets the wild-type 69-70 sequence as an internal  
63 control. We further evaluate the performance of this assay in combination with our previously described  
64 RT-qPCR assay for the detection of L452R, E484K, and N501Y (28), and demonstrate the utility of this  
65 targeted mutational analysis to accurately distinguish among VOCs.

## 66 MATERIALS AND METHODS

67

### 68 *Assay Design*

69 The spike protein mutations associated with each variant that are interrogated by the RT-qPCR assays  
70 are summarized in Figure 1. In the first reaction (Reaction 1), we utilized our previously described RT-  
71 qPCR assay to detect L452R, E484K, and N501Y mutations in spike Receptor Binding Domain (RBD)  
72 (28). The present study describes the combination of this assay with a second, newly designed reaction  
73 (Reaction 2), which detects the deletion of amino acids 69-70 in the spike N-Terminal Domain (del69-70),  
74 as well as K417N and T478K mutations in the RBD. We use allele-specific RT-qPCR with probe  
75 sequences designed to maximize the difference in annealing temperature between mutant and wild-type  
76 sequences, allowing for differential binding and amplification. The primer/probe sequences for each  
77 mutation site are summarized in Table 1, and the guidance for interpretation and reporting is described in  
78 Table 2. Additional details are provided in the Supplemental Methods, ssDNA sequences for analytical  
79 experiments (Supplemental Table 1), analytical validation data (Supplemental Table 2), and in-silico  
80 analysis of primer and probe sequences (Supplemental Figure 1).

81

### 82 *Clinical Specimens*

83 The samples included in the initial phase of this study were upper respiratory swab specimens collected  
84 from patients as part of routine clinical care from April 26, 2021 to August 1, 2021. Testing was performed  
85 at Stanford Clinical Virology Laboratory, which provides virologic testing for all Stanford-affiliated hospitals  
86 and outpatient centers in the San Francisco Bay Area. These initial SARS-CoV-2 nucleic acid  
87 amplification tests (NAATs) tests prior to genotyping were conducted according to manufacturer and  
88 emergency authorization instructions as previously described (28), and in the Supplemental Methods. All  
89 samples that tested positive for SARS-CoV-2 RNA were reflexed to genotyping. We then excluded  
90 samples that were initially tested by laboratory-based methods with cycle threshold values (Ct)  $\geq 35$  or  
91 relative light units (RLU)  $\leq 1100$ . We included all available samples initially tested at or near the point of  
92 care as Ct data was not readily available for real-time specimen triage for these samples. We also  
93 excluded follow-up specimens to eliminate patient-level duplicates. Subsequent validation of this assay

94 for Omicron variant detection was conducted using a convenience set of 230 Omicron variant samples  
95 with available WGS data collected between December 2, 2021 and January 5, 2022. This study was  
96 conducted with Stanford institutional review board approval (protocol 57519), and individual consent was  
97 waived.

98

### 99 *Whole-Genome Sequencing*

100 To validate the genotyping RT-qPCR reactions, we tested their performance against WGS in a subset of  
101 the samples in the initial April 26, 2021 to August 1, 2021 cohort with Ct <30. Samples with non-dominant  
102 variant typing by RT-qPCR were prioritized for sequencing, with the remaining isolates chosen randomly  
103 to fill a sequencing run. WGS was conducted as described previously, using a lab-developed pipeline  
104 consisting of long-range PCR, followed by fragmentation, then single-end 150-cycle sequencing using  
105 MiSeq reagent kit V3 (Illumina, San Diego, CA) (28). Genomes were assembled via a custom assembly  
106 and bioinformatics pipeline using NCBI NC\_045512.2 as reference. Whole-genome sequences with  $\geq 75\%$   
107 genome coverage to a depth of at least 10 reads were accepted for interpretation. Mutation calling  
108 required a depth of at least 12 reads with a minimum variant frequency of 20%. PANGO lineage  
109 assignment was performed using <https://pangolin.cog-uk.io/> running pangolin version 3.1.17, while  
110 Nextclade Web v1.13.1 and auspice.us 0.8.0. were used to perform phylogenetic placement (3, 29, 30).  
111 Both lineage and clade assignments were performed on February 1, 2022. WGS data was deposited in  
112 GISAID (Supplemental Table 3).

113

### 114 *Statistical Analysis*

115 Positive percent agreement (PPA) and negative percent agreement (NPA) were reported with Clopper-  
116 Pearson score 95% binomial confidence intervals (CI) using WGS as the reference method. Analyses  
117 were conducted using the R statistical software package. This study was reported in accordance with  
118 Standards for the Reporting of Diagnostic Accuracy Studies (STARD) guidelines.

## 119 RESULTS

120

121 During the initial study period of April 26, 2021 to August 1, 2021, the Stanford Clinical Virology  
122 Laboratory received 102,158 specimens from 70,544 unique individuals. A total of 1,657 samples from  
123 unique individuals tested positive for SARS-CoV-2, of which 1,093 (66%) had genotyping RT-qPCR  
124 Reaction 1 and Reaction 2 performed, and 502 (30.3%) had successful WGS performed (Supplemental  
125 Figure 2). The lower limit of detection for the mutation site probes in Reaction 2 (in copies per  $\mu$ L template)  
126 were 14.8 for del69-70 (HEX), 16.4 for K417N (CY5), and 2.1 for T478K (FAM). Median number of  
127 aligned reads for WGS was 485,870 (interquartile range [IQR] 289,363-655,481), while median genome  
128 coverage to a depth of at least 10 reads was 99.3% (IQR 97.1-99.3%). Of note, Reaction 1 was  
129 performed in near real-time, while Reaction 2 was performed retrospectively. Overall, this subset of  
130 sequenced samples, had patient and testing characteristics that closely resembled those of the larger  
131 cohorts (Supplemental Table 4).

132

133 The assay resulted as “Unable to Genotype” in 152 of 1,093 samples (14%) due to lack of amplification of  
134 any target in either or both reactions. Assay failure occurred predominantly in samples originally tested at  
135 or near the point of care (119/341, 35%), where all positive samples were triaged for genotyping without  
136 any filter. In contrast, assay failure occurred much less frequently in samples originally tested in the  
137 moderate-to-high complexity virology lab (33/752, 4%), where samples with lower viral RNA levels (Ct  
138  $\geq$ 35) were not triaged for genotyping. In the latter group of 752 samples tested in the virology lab, 601 had  
139 known Ct values. Among these 601 samples, 68 had Ct > 30, of which 11/68 (16%) failed amplification.

140

141 PPA and NPA for the six individual mutations targeted by the genotyping RT-qPCRs as compared to  
142 WGS were calculated from the 502 samples with both RT-qPCR and WGS performed (Supplemental  
143 Figure 2). The number of samples positive for each mutation reflects the natural prevalence of each of  
144 these mutations during this time period. For the combination of Reactions 1 and 2, the PPAs for del69-70,  
145 L452R, T478K, E484K, and N501Y were 100% (Table 3). Across all six loci, only K417N had a false  
146 negative, resulting in a PPA of 96% (27/28). In this sample, WGS showed a synonymous T to C mutation

147 at position 1254 of the spike gene corresponding to amino acid position 418, changing the codon from  
148 ATT to ATC. This single base pair substitution likely decreased the annealing temperature, causing probe  
149 dropout and a false negative result.

150

151 The NPAs for del69-70, K417N, T478K, and N501Y were 100% (Table 3). L452R had an NPA of 95%  
152 (94/99) and E484K had an NPA of 99% (464/467). At the L452 locus, there were five samples positive for  
153 L452R mutation by RT-qPCR that were negative by WGS. Manual review of the WGS data showed that  
154 these were likely false negative WGS results due to insufficient (<12 reads) coverage at this codon. There  
155 were 3-9 reads containing the L452R mutation identified in the WGS primary data in each of these five  
156 samples. These five samples were all in the Delta lineage based on mutations found at other positions by  
157 sequencing.

158

159 For the E484K target, there were three samples that tested positive for the E to K mutation but in fact had  
160 a E484Q mutation determined by WGS. In both the E to K mutation (GAA to AAA) as well as the E to Q  
161 mutation (GAA to CAA), there was a single base substitution at the first position of the codon resulting in  
162 nonspecific probe binding. These three samples had a distinct blunted amplification curve with high Ct  
163 values associated with E484Q, as previously described (31). While this cross-reactivity is a limitation of  
164 the E484K probe design, the unusually-shaped amplification curves were identified and flagged for  
165 medical director review as part of assay interpretation protocol (Table 2). Presumptive typing for such  
166 cases would need to be deferred until WGS confirmation.

167

168 Of note, there was a subset of variant AY.2, involving four specimens in our cohort, that had a V70F  
169 mutation causing both del69-70 and wt69-70 probes not to bind. However, because this variant would  
170 have T478K and K417N detected, the wt69-70 signal was not needed as an amplification control. This  
171 subset of the AY.2 genotype is expected to be positive for L452R and N501 wildtype internal control while  
172 negative for N501Y and E484K in Reaction 1, and positive for K417N and T478K while negative for  
173 del69-70 and wildtype 69-70 internal control in Reaction 2. This scenario has been reflected in the clinical  
174 interpretation table (Table 2).

175  
176 SARS-CoV-2 positive specimens collected starting December 2, 2021 began to show an unusual  
177 combination of mutations: presence of K417N and del69-70 only in Reaction 2, with all targets including  
178 internal control N501 not detected in Reaction 1. Based on in-silico analysis, we determined that these  
179 cases likely represented the Omicron variant. While most Omicron variant strains possess del69-70,  
180 K417N, T478K, and N501Y mutations, they also have mutations at A67V, S477N, and Q498R, which  
181 would be predicted to interfere with binding of the del69-70/wt69-70, T478K, and N501Y/N501 probes,  
182 respectively. Although the E484K probe demonstrated cross-reactivity with strains containing the E484Q  
183 mutation, as described above, the E484K probe did not detect the E484A mutation in the Omicron variant  
184 since it differed by two or more bases. The del69-70 probe likely was able to retain some degree of  
185 binding due to the wider melting temperature differential of a 6-nucleotide deletion compared to a point  
186 mutation. As such, we validated this assay for Omicron detection using a set of 230 SARS-CoV-2 positive  
187 samples confirmed to be Omicron by WGS. We found that the unique pattern of K417N and del69-70 in  
188 Reaction 2, along with failure to amplify any target including internal control in Reaction 1, was present in  
189 230/230 (100%, 95% CI 98-100%) Omicron samples tested. This pattern was not seen in any of the  
190 1,093 non-Omicron samples previously genotyped.

191  
192 We next predicted the WHO variant designation of samples using RT-qPCR and correlated them with the  
193 PANGO lineage assignments based on WGS data (Table 4). Mapping the genotyping results of the  
194 cohort based on RT-qPCR mutation analysis onto the Nextclade phylogenetic tree demonstrated close  
195 correlation with their WHO variant designations (Figure 2). Among the 732 clinical samples that were  
196 tested by both RT-qPCR and WGS, 43 samples (5.9%) were Alpha (B.1.1.7 or Q.3), 2 samples (0.3%)  
197 were Beta (B.1.351), 20 samples (2.7%) were Gamma (P.1 and sublineages), 378 samples (51.6%) were  
198 Delta (B.1.617.2 or AY sublineages), and 230 samples (31.4%) were Omicron (B.1.1.529 or BA  
199 sublineages). There were no RT-qPCR false negatives in assigning samples to these lineages. In  
200 addition, there were 59 samples (8.1%) tested by WGS that did not correspond to a WHO VOC as of  
201 February 2, 2022. Within this subset, there were 4 samples that were erroneously assigned as Gamma  
202 and 1 that was assigned as Beta by RT-qPCR. By WGS, these samples were variant of interest (VOI) Mu



203 (B.1.621 or BB.2). This variant shares mutations E484K and N501Y with both the Beta and Gamma  
204 variants. A subset of Mu also includes the K417N mutation which is seen in the Beta variant. Thus, our  
205 PCR assay could not distinguish VOI Mu from VOCs Beta and Gamma. Our interpretation table  
206 information reflects this limitation (Table 2). The remaining 54 samples did not contain mutation patterns  
207 associated with VOCs by either RT-qPCR or WGS.

## 208 **DISCUSSION**

209

210 The ability to distinguish between SARS-CoV-2 VOCs is important for epidemiologic surveillance, and in  
211 certain circumstances, the care of individual COVID-19 patients. In this study, we describe a two-reaction,  
212 multiplex RT-qPCR genotyping approach that examines the spike mutations del69-70, K417N, L452R,  
213 T478K, E484K, and N501Y. This targeted mutational analysis can be used to differentiate between the  
214 WHO VOCs Alpha (B.1.1.7 and sublineages), Beta (B.1.351), Gamma (P.1 and sublineages), Delta  
215 (B.1.617.2 and sublineages), and Omicron (B.1.1.529 and sublineages), as well as identify samples  
216 which cannot be categorized into a known VOC or VOI. Because the first part of this approach, Reaction  
217 1, has been previously described, this current study focuses on Reaction 2 and the integrated results of  
218 the two-reaction test (28). Overall, these reactions showed high concordance with WGS, demonstrating  
219 PPA 96-100% and NPA 95-100% for all targeted mutations.

220

221 Several groups have previously described similar approaches to SARS-CoV-2 variant determination by  
222 RT-qPCR and digital droplet RT-PCR, particularly for the spike del69-70, E484K, and N501Y positions  
223 (32-39). Some of these assays included additional mutation sites that were not in our study, such as spike  
224 del144 or ORF1a  $\Delta$ 3675–3677 (32, 38). These earlier assays, published prior to the rise of Delta,  
225 primarily targeted VOCs Alpha, Beta, and Gamma. This was then followed by a surge of reports on the  
226 detection of the Delta variant. Garson et al. utilized double-mismatch allele-specific RT-PCR at L452R  
227 and T478K to differentiate Delta variant from other VOCs in 42 UK patient samples (40). Aoki et al.  
228 described an approach that combines nested PCR along with high-resolution melting analysis at those  
229 same mutations, which was validated in a small Japanese patient cohort (41). Barua et al. used a slightly  
230 different approach, taking advantage of the difference in melting temperature of a probe targeted to Delta  
231 mutation in spike T478K compared to other variants for a Delta-specific RT-FRET-PCR assay (42).  
232 Another defining feature of VOC Delta is spike del156-157, which was the target of a Delta variant PCR  
233 test developed by Hamill et al. (43). To our knowledge, the two-reaction multiplex RT-qPCR approach  
234 outlined in this study examining six different mutation sites is the most comprehensive variant genotyping  
235 test described that can identify Alpha, Beta, Gamma, Delta, and Omicron variants.

236

237 Multiplex RT-qPCR SARS-CoV-2 genotyping takes advantage of a commonly-used molecular technique  
238 that can be implemented by laboratories using existing equipment, materials, and personnel. Because  
239 this assay is more accessible and has a more rapid turnaround time than WGS, we envision it serving a  
240 complimentary role to sequencing. The genotyping RT-qPCR can provide more detailed and up-to-date  
241 epidemiological information by increasing the sample size of categorized variants in each geographic  
242 region, and can be essential in tracking local outbreaks in areas without direct access to WGS. For  
243 individual patients, the turnaround time of several hours also allows it to directly impact clinical care. For  
244 example, VOCs show differential susceptibility to monoclonal antibody treatments, and variant reporting  
245 could include this information (Table 2) (2). Furthermore, current ongoing trials for small molecule drugs  
246 and other treatments may yield more information about variant-specific treatment strategies.

247

248 Sequencing, however, is still needed for the identification and confirmation of novel variants. This is  
249 evidenced by the 5 VOI Mu samples originally mis-identified by RT-qPCR as Gamma and Beta. The two  
250 approaches are complementary in nature, and RT-qPCR genotyping can help triage or prioritize samples  
251 for sequencing. For example, pre-screening by RT-qPCR can enrich for samples with atypical mutation  
252 patterns, lead to more efficient use of sequencing resources, and potentially, more rapid identification of  
253 new variants.

254

255 This RT-qPCR approach has several limitations as evidenced by its assay failure rate of 14% across all  
256 tested samples in our initial cohort. Because multiplex RT-qPCRs involve a mixture of multiple sets of  
257 primers and probes, they are inherently less analytically sensitive than single-target assays. For samples  
258 with RNA concentrations near the lower limits of detection, freeze-thaw cycles could impact RNA stability,  
259 and may not yield consistent results due to stochastic variation. This issue could be alleviated by  
260 implementing a Ct/RLU filter to only genotype samples most likely to yield interpretable results. Within our  
261 1,093 sample cohort, the lower assay failure rate in samples tested in our clinical virology laboratory (4%)  
262 compared to near-care settings (35%) is likely attributable to genotyping only specimens with higher viral  
263 RNA levels. Note, however, that even with such filtering, mutation analysis by RT-qPCR remains more

264 analytically sensitive than WGS. This study is also limited by the absence of VOC co-infections, such as  
265 with Delta and Omicron, though we anticipate that this RT-qPCR approach would be able to detect such  
266 cases. Future experiments will be required to confirm detection of VOC co-infections, including at different  
267 viral RNA levels and variant proportions.

268

269 Another limitation to this approach is the continuously evolving variant landscape which may render such  
270 a targeted assay obsolete over a relatively short period of time. First, it is important to take into account  
271 that the loss of expected internal control signal for the N501 and/or wt69-70 targets in known SARS-CoV-  
272 2 RNA positive samples is itself useful information, analogous to the widely-used Spike Gene Target  
273 Failure (36). Furthermore, the inclusion of multiple mutations in key residues that influence viral fitness  
274 and antibody escape helps guard against rapid obsolescence, as evidenced by the ability of the RT-  
275 qPCR approach to rapidly detect emergence of the Omicron variant in our population, as well as all major  
276 variant replacements that occurred in 2021. Notably, this approach also revealed emerging community  
277 transmission of BA.2 in early 2022; with K417N and wt69-70 detected in Reaction 2, and all targets  
278 including N501 not detected in Reaction 1. Nevertheless, flexibility and vigilance are required should re-  
279 design and re-validation be required as novel variants emerge.

280

281 In summary, we developed and validated a two-reaction multiplex RT-qPCR genotyping strategy that  
282 interrogates six clinically relevant mutations within the SARS-CoV-2 spike: del69-70, K417N, L452R,  
283 T478K, E484K, and N501Y. This approach allows for identification of WHO VOCs Alpha, Beta, Gamma,  
284 Delta and Omicron with excellent concordance to WGS. Overall, this method complements WGS, and is  
285 suitable for clinical decision-making, near real-time variant surveillance, and the triage of samples for  
286 sequencing.

287 **ACKNOWLEDGEMENTS**

288 We would like to thank the Stanford Clinical Virology Laboratory Staff for their excellence and  
289 perseverance in caring for our community while facing the unique challenges of this pandemic. We  
290 additionally are grateful to the Stanford Protein and Nucleic Acid Facility for their synthesis of reagents on  
291 short notice.

292 **REFERENCES**

293

- 294 1. World Health Organization. February 22, 2022. Tracking SARS-CoV2 Variants.  
295 <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/> Accessed February 28, 2022.
- 296 2. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Fera D, Shafer RW.  
297 2021. The biological and clinical significance of emerging SARS-CoV-2 variants. *Nat Rev Genet*  
298 *22:757-773*.
- 299 3. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T,  
300 Neher RA. 2018. Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics* 34:4121-  
301 4123.
- 302 4. Day T, Gandon S, Lion S, Otto SP. 2020. On the evolutionary epidemiology of SARS-CoV-2. *Curr*  
303 *Biol* 30:R849-R857.
- 304 5. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CAB, Russell  
305 TW, Tully DC, Washburne AD, Wenseleers T, Gimma A, Waites W, Wong KLM, van Zandvoort K,  
306 Silverman JD, Group CC-W, Consortium C-GU, Diaz-Ordaz K, Keogh R, Eggo RM, Funk S, Jit M,  
307 Atkins KE, Edmunds WJ. 2021. Estimated transmissibility and impact of SARS-CoV-2 lineage  
308 B.1.1.7 in England. *Science* 372.
- 309 6. Muik A, Wallisch AK, Sanger B, Swanson KA, Muhl J, Chen W, Cai H, Maurus D, Sarkar R,  
310 Tureci O, Dormitzer PR, Sahin U. 2021. Neutralization of SARS-CoV-2 lineage B.1.1.7  
311 pseudovirus by BNT162b2 vaccine-elicited human sera. *Science* 371:1152-1153.
- 312 7. Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, Liu L, Kwong PD, Huang Y, Shapiro L,  
313 Ho DD. 2021. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. *Cell*  
314 *Host Microbe* 29:747-751 e4.
- 315 8. Collier DA, De Marco A, Ferreira I, Meng B, Datir RP, Walls AC, Kemp SA, Bassi J, Pinto D,  
316 Silacci-Fregni C, Bianchi S, Tortorici MA, Bowen J, Culap K, Jaconi S, Camerini E, Snell G,  
317 Pizzuto MS, Pellanda AF, Garzoni C, Riva A, Collaboration C-NBC-, Elmer A, Kingston N, Graves  
318 B, McCoy LE, Smith KGC, Bradley JR, Temperton N, Ceron-Gutierrez L, Barcenas-Morales G,  
319 Consortium C-GU, Harvey W, Virgin HW, Lanzavecchia A, Piccoli L, Doffinger R, Wills M, Velesler

- 320 D, Corti D, Gupta RK. 2021. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited  
321 antibodies. *Nature* 593:136-141.
- 322 9. Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, Yoon H, Li D, Haynes BF, Sanders  
323 KO, Gnanakaran S, Hengartner N, Pajon R, Smith G, Dubovsky F, Glenn GM, Korber B,  
324 Montefiori DC. 2021. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited  
325 by ancestral Spike vaccines. *bioRxiv* doi:10.1101/2021.01.27.428516.
- 326 10. Karim SSA. 2021. Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of  
327 protection. *Lancet* 397:1263-1264.
- 328 11. Bolze A, Cirulli ET, Luo S, White S, Wyman D, Rossi AD, Machado H, Cassens T, Jacobs S,  
329 Schiabor Barrett KM, Tsan K, Nguyen J, Ramirez JM, Sandoval E, Wang X, Wong D, Becker D,  
330 Laurent M, Lu JT, Isaksson M, Washington NL, Lee W. 2021. SARS-CoV-2 variant Delta rapidly  
331 displaced variant Alpha in the United States and led to higher viral loads. *medRxiv*  
332 doi:10.1101/2021.06.20.21259195:2021.06.20.21259195.
- 333 12. Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ET, Schiabor Barrett KM, Larsen BB,  
334 Anderson C, White S, Cassens T, Jacobs S, Levan G, Nguyen J, Ramirez JM, Rivera-Garcia C,  
335 Sandoval E, Wang X, Wong D, Spencer E, Robles-Sikisaka R, Kurzban E, Hughes LD, Deng X,  
336 Wang C, Servellita V, Valentine H, De Hoff P, Seaver P, Sathe S, Gietzen K, Sickler B, Antico J,  
337 Hoon K, Liu J, Harding A, Bakhtar O, Basler T, Austin B, Isaksson M, Febbo P, Becker D, Laurent  
338 M, McDonald E, Yeo GW, Knight R, Laurent LC, de Feo E, Worobey M, Chiu C, Suchard MA, et  
339 al. 2021. Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2  
340 B.1.1.7 in the United States. *medRxiv* doi:10.1101/2021.02.06.21251159.
- 341 13. Chen X, Chen Z, Azman AS, Sun R, Lu W, Zheng N, Zhou J, Wu Q, Deng X, Zhao Z, Chen X, Ge  
342 S, Yang J, Leung DT, Yu H. 2021. Neutralizing antibodies against SARS-CoV-2 variants induced  
343 by natural infection or vaccination: a systematic review and pooled meta-analysis. *Clin Infect Dis*  
344 doi:10.1093/cid/ciab646.
- 345 14. Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer AJ, Ginn HM, Zhao Y, Duyvesteyn HME,  
346 Nutalai R, Tuekprakhon A, Wang B, Paesen GC, Slon-Campos J, Lopez-Camacho C, Hallis B,  
347 Coombes N, Bewley KR, Charlton S, Walter TS, Barnes E, Dunachie SJ, Skelly D, Lumley SF,

- 348 Baker N, Shaik I, Humphries HE, Godwin K, Gent N, Sienkiewicz A, Dold C, Levin R, Dong T,  
349 Pollard AJ, Knight JC, Klenerman P, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye  
350 M, Belij-Rammerstorfer S, Gilbert S, Hall DR, Williams MA, Paterson NG, James W, Carroll MW,  
351 Fry EE, Mongkolsapaya J, et al. 2021. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by  
352 convalescent and vaccine sera. *Cell* 184:2201-2211 e7.
- 353 15. Hoffmann M, Arora P, Gross R, Seidel A, Hornich BF, Hahn AS, Kruger N, Graichen L, Hofmann-  
354 Winkler H, Kempf A, Winkler MS, Schulz S, Jack HM, Jahrsdorfer B, Schrezenmeier H, Muller M,  
355 Kleger A, Munch J, Pohlmann S. 2021. SARS-CoV-2 variants B.1.351 and P.1 escape from  
356 neutralizing antibodies. *Cell* 184:2384-2393 e12.
- 357 16. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, Nutalai R, Zhou D, Mentzer  
358 AJ, Zhao Y, Duyvesteyn HME, Lopez-Camacho C, Slon-Campos J, Walter TS, Skelly D, Johnson  
359 SA, Ritter TG, Mason C, Costa Clemens SA, Gomes Naveca F, Nascimento V, Nascimento F,  
360 Fernandes da Costa C, Resende PC, Pauvolid-Correa A, Siqueira MM, Dold C, Temperton N,  
361 Dong T, Pollard AJ, Knight JC, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye M,  
362 Belij-Rammerstorfer S, Gilbert SC, Malik T, Carroll MW, Klenerman P, Barnes E, Dunachie SJ,  
363 Baillie V, Serafin N, Ditse Z, Da Silva K, Paterson NG, Williams MA, et al. 2021. Reduced  
364 neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. *Cell* 184:4220-4236  
365 e13.
- 366 17. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot  
367 F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-Chikhani N,  
368 Edriss D, Belec L, Seve A, Courtellemont L, Pere H, Hocqueloux L, Fafi-Kremer S, Prazuck T,  
369 Mouquet H, Bruel T, Simon-Loriere E, Rey FA, Schwartz O. 2021. Reduced sensitivity of SARS-  
370 CoV-2 variant Delta to antibody neutralization. *Nature* 596:276-280.
- 371 18. Liu J, Liu Y, Xia H, Zou J, Weaver SC, Swanson KA, Cai H, Cutler M, Cooper D, Muik A, Jansen  
372 KU, Sahin U, Xie X, Dormitzer PR, Shi PY. 2021. BNT162b2-elicited neutralization of B.1.617 and  
373 other SARS-CoV-2 variants. *Nature* 596:273-275.
- 374 19. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, Dushoff J,  
375 Mlisana K, Moultrie H. 2021. Increased risk of SARS-CoV-2 reinfection associated with



- 376 emergence of the Omicron variant in South Africa. medRxiv  
377 doi:10.1101/2021.11.11.21266068:2021.11.11.21266068.
- 378 20. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, Metzler M, Kohmer N, Hoehl S,  
379 Helfritz FA, Wolf T, Goetsch U, Ciesek S. 2021. Reduced Neutralization of SARS-CoV-2 Omicron  
380 Variant by Vaccine Sera and monoclonal antibodies. medRxiv  
381 doi:10.1101/2021.12.07.21267432:2021.12.07.21267432.
- 382 21. Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, Bolland WH,  
383 Porrot F, Staropoli I, Lemoine F, Pere H, Veyer D, Puech J, Rodary J, Baele G, Dellicour S,  
384 Raymenants J, Gorissen S, Geenen C, Vanmechelen B, Wawina-Bokalanga T, Marti-Carreras J,  
385 Cuypers L, Seve A, Hocqueloux L, Prazuck T, Rey F, Simon-Loriere E, Bruel T, Mouquet H,  
386 Andre E, Schwartz O. 2021. Considerable escape of SARS-CoV-2 Omicron to antibody  
387 neutralization. Nature doi:10.1038/s41586-021-04389-z.
- 388 22. Salvatore M, Bhattacharyya R, Purkayastha S, Zimmermann L, Ray D, Hazra A, Kleinsasser M,  
389 Mellan T, Whittaker C, Flaxman S, Bhatt S, Mishra S, Mukherjee B. 2021. Resurgence of SARS-  
390 CoV-2 in India: Potential role of the B.1.617.2 (Delta) variant and delayed interventions. medRxiv  
391 doi:10.1101/2021.06.23.21259405:2021.06.23.21259405.
- 392 23. Wang L, Cheng G. 2021. Sequence analysis of the emerging SARS-CoV-2 variant Omicron in  
393 South Africa. J Med Virol doi:10.1002/jmv.27516.
- 394 24. Zhang W, Davis BD, Chen SS, Sincuir Martinez JM, Plummer JT, Vail E. 2021. Emergence of a  
395 Novel SARS-CoV-2 Variant in Southern California. JAMA 325:1324-1326.
- 396 25. Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, Scott R, Sconza R, Price J,  
397 Margaritis M, Bergstrom M, Spyer MJ, Miralhes PB, Grant P, Kirk S, Valerio C, Mangera Z,  
398 Prabhakar T, Moreno-Cuesta J, Arulkumaran N, Singer M, Shin GY, Sanchez E,  
399 Paraskevopoulou SM, Pillay D, McKendry RA, Mirfenderesky M, Houlihan CF, Nastouli E. 2021.  
400 Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in  
401 London, UK: a whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis  
402 21:1246-1256.
- 403 26. GISAID. 2022. Tracking of Variants. <https://www.gisaid.org/>. Accessed February 1, 2022.

- 404 27. Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, Datir R, Collier DA, Albecka  
405 A, Singh S, Pandey R, Brown J, Zhou J, Goonawardane N, Mishra S, Whittaker C, Mellan T,  
406 Marwal R, Datta M, Sengupta S, Ponnusamy K, Radhakrishnan VS, Abdullahi A, Charles O,  
407 Chattopadhyay P, Devi P, Caputo D, Peacock T, Wattal C, Goel N, Satwik A, Vaishya R, Agarwal  
408 M, Chauhan H, Dikid T, Gogia H, Lall H, Verma K, Dhar MS, Singh MK, Soni N, Meena N, Madan  
409 P, Singh P, Sharma R, Sharma R, Kabra S, Kumar S, Kumari S, Sharma U, et al. 2021. SARS-  
410 CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature* 599:114-119.
- 411 28. Wang H, Miller JA, Verghese M, Sibai M, Solis D, Mfuh KO, Jiang B, Iwai N, Mar M, Huang C,  
412 Yamamoto F, Sahoo MK, Zehnder J, Pinsky BA. 2021. Multiplex SARS-CoV-2 Genotyping  
413 Reverse Transcriptase PCR for Population-Level Variant Screening and Epidemiologic  
414 Surveillance. *J Clin Microbiol* 59:e0085921.
- 415 29. Sagulenko P, Puller V, Neher RA. 2018. TreeTime: Maximum-likelihood phylodynamic analysis.  
416 *Virus Evol* 4:vex042.
- 417 30. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D,  
418 Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen  
419 JF, Group S. 2015. STARD 2015: an updated list of essential items for reporting diagnostic  
420 accuracy studies. *BMJ* 351:h5527.
- 421 31. Verghese M, Jiang B, Iwai N, Mar M, Sahoo MK, Yamamoto F, Mfuh KO, Miller J, Wang H,  
422 Zehnder J, Pinsky BA. 2021. A SARS-CoV-2 Variant with L452R and E484Q Neutralization  
423 Resistance Mutations. *J Clin Microbiol* 59:e0074121.
- 424 32. Borsova K, Paul ED, Kovacova V, Radvanszka M, Hajdu R, Cabanova V, Slavikova M, Lickova M,  
425 Lukacikova L, Belak A, Roussier L, Kosticova M, Liskova A, Madarova L, Stefkovicova M,  
426 Reizigova L, Novakova E, Sabaka P, Koscalova A, Brejova B, Staronova E, Misik M, Vinar T,  
427 Nosek J, Cekan P, Klempa B. 2021. Surveillance of SARS-CoV-2 lineage B.1.1.7 in Slovakia  
428 using a novel, multiplexed RT-qPCR assay. *Sci Rep* 11:20494.
- 429 33. Korukluoglu G, Kolukirik M, Bayrakdar F, Ozgumus GG, Altas AB, Cosgun Y, Ketre Kolukirik CZ.  
430 2021. 40 minutes RT-qPCR Assay for Screening Spike N501Y and HV69-70del Mutations.  
431 bioRxiv doi:10.1101/2021.01.26.428302:2021.01.26.428302.

- 432 34. Perchetti GA, Zhu H, Mills MG, Shrestha L, Wagner C, Bakhsh SM, Lin MJ, Xie H, Huang ML,  
433 Mathias P, Bedford T, Jerome KR, Greninger AL, Roychoudhury P. 2021. Specific allelic  
434 discrimination of N501Y and other SARS-CoV-2 mutations by ddPCR detects B.1.1.7 lineage in  
435 Washington State. *J Med Virol* 93:5931-5941.
- 436 35. Banada P, Green R, Banik S, Chopoorian A, Streck D, Jones R, Chakravorty S, Alland D. 2021.  
437 A Simple Reverse Transcriptase PCR Melting-Temperature Assay To Rapidly Screen for Widely  
438 Circulating SARS-CoV-2 Variants. *J Clin Microbiol* 59:e0084521.
- 439 36. Bal A, Destras G, Gaymard A, Stefic K, Marlet J, Eymieux S, Regue H, Semanas Q, d'Aubarede  
440 C, Billaud G, Laurent F, Gonzalez C, Mekki Y, Valette M, Bouscambert M, Gaudy-Graffin C, Lina  
441 B, Morfin F, Josset L, Group CO-DHS. 2021. Two-step strategy for the identification of SARS-  
442 CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France,  
443 August to December 2020. *Euro Surveill* 26.
- 444 37. Neopane P, Nypaver J, Shrestha R, Beqaj SS. 2021. SARS-CoV-2 Variants Detection Using  
445 TaqMan SARS-CoV-2 Mutation Panel Molecular Genotyping Assays. *Infect Drug Resist* 14:4471-  
446 4479.
- 447 38. Vogels CBF, Breban MI, Ott IM, Alpert T, Petrone ME, Watkins AE, Kalinich CC, Earnest R,  
448 Rothman JE, Goes de Jesus J, Morales Claro I, Magalhaes Ferreira G, Crispim MAE, Brazil  
449 UKCGN, Singh L, Tegally H, Anyaneji UJ, Network for Genomic Surveillance in South A, Hodcroft  
450 EB, Mason CE, Khullar G, Metti J, Dudley JT, MacKay MJ, Nash M, Wang J, Liu C, Hui P,  
451 Murphy S, Neal C, Laszlo E, Landry ML, Muyombwe A, Downing R, Razeq J, de Oliveira T, Faria  
452 NR, Sabino EC, Neher RA, Fauver JR, Grubaugh ND. 2021. Multiplex qPCR discriminates  
453 variants of concern to enhance global surveillance of SARS-CoV-2. *PLoS Biol* 19:e3001236.
- 454 39. Hale R, Crowley P, Dervisevic S, Coupland L, Cliff PR, Ebie S, Snell LB, Paul J, Williams C,  
455 Randell P, Pond M, Stanley K. 2021. Development of a Multiplex Tandem PCR (MT-PCR) Assay  
456 for the Detection of Emerging SARS-CoV-2 Variants. *Viruses* 13.
- 457 40. Garson JA, Badru S, Parker E, Tedder RS, McClure MO. 2022. Highly sensitive and specific  
458 detection of the SARS-CoV-2 Delta variant by double-mismatch allele-specific real time reverse  
459 transcription PCR. *J Clin Virol* 146:105049.

- 460 41. Aoki A, Adachi H, Mori Y, Ito M, Sato K, Okuda K, Sakakibara T, Okamoto Y, Jinno H. 2021. A  
461 rapid screening assay for L452R and T478K spike mutations in SARS-CoV-2 Delta variant using  
462 high-resolution melting analysis. *J Toxicol Sci* 46:471-476.
- 463 42. Barua S, Hoque M, Kelly PJ, Bai J, Hanzlicek G, Noll L, Walz H, Johnson C, Kyriakis C, Wang C.  
464 2021. High-resolution melting curve FRET-PCR rapidly identifies SARS-CoV-2 mutations. *J Med*  
465 *Viro* 93:5588-5593.
- 466 43. Hamill V, Noll L, Lu N, Tsui WNT, Porter EP, Gray M, Sebhatu T, Goerl K, Brown S, Palinski R,  
467 Thomason S, Almes K, Retallick J, Bai J. 2021. Molecular detection of SARS-CoV-2 strains and  
468 differentiation of Delta variant strains. *Transbound Emerg Dis* doi:10.1111/tbed.14443.
- 469
- 470

471 **FIGURE LEGENDS**

472

473 **Figure 1.** Summary of current World Health Organization (WHO)-designated variants of concern (VOC)  
474 along with their expected spike mutations at sites targeted by this two-reaction multiplex SARS-CoV-2  
475 RT-qPCR genotyping approach. These reactions are designed to detect the following mutations: del69-70,  
476 K417N, L452R, T478K, E484K, and N501Y. Shading indicates predicted versus empiric performance of  
477 this assay for the detection and differentiation of these VOCs. The predicted detection for the VOC  
478 Omicron is based on both the sequence at the target sites and known adjacent mutations in the probe  
479 binding site. A single asterisk and double asterisk respectively denote a known limitations of the assay in  
480 differentiating VOCs Beta and Gamma respectively from the variant of interest Mu.

481

482 **Figure 2.** Nextclade phylogenetic tree of 3,097 SARS-CoV-2 genomes, including all 732 of the  
483 sequenced genomes from this study, and 2,365 genomes from the Nextstrain global reference tree as of  
484 February 2, 2022. The 732 included genomes are colored by RT-qPCR genotyping predicted variant type,  
485 with each circle representing a sequenced genome. Branch length corresponds to nucleotide divergence.  
486 Sequenced genomes span the breadth of the reference tree. Annotation to the right of the tree  
487 demonstrates the variant type based on whole-genome sequencing (WGS). Variant determination by RT-  
488 qPCR matched WGS except for 1 sequence typed as Beta, and 4 sequences typed as Gamma by RT-  
489 qPCR which clustered with variant of interest Mu by WGS.

490

491 **TABLES**

492

493 **Table 1.** Reaction 2 Primer and Probe Oligonucleotide Sequences

494

	<b>Name</b>	<b>Sequence (5' → 3')</b>	<b>Final Concentration</b>
Primers	del69-70_FWD	CATTAAATGGTAGGACAGGGTTA	300 nM
	del69-70_REV	ACATTCAACTCAGGACTTGTT	300 nM
	K417N_FWD	GCAGCCTGATAAATCATCTG	300 nM
	K417N_REV	CATTTGTAATTAGAGGTGATGAAGTC	300 nM
	T478K_FWD	AAAGGAAAGTAACAATTAACCT	300 nM
	T478K_REV	AGGAAGTCTAATCTCAAACCT	300 nM
Probes	del69-70_MT_HEX	HEX-TTGGTCCCAGAGATAGCATG-BHQ1	50 nM
	wt69-70_WT_CY3.5 <sup>a</sup>	CY3.5-GGTCCCAGAGACATGTATAG-BHQ2	50 nM
	K417N_MT_CY5	CY5-TAATCAGCAATATTTCCAGT-BHQ2	50 nM
	T478K_MT_FAM	FAM-ACCATTACAAGGTTTGCTAC-BHQ1	50 nM

495 FWD, forward; REV, reverse; WT, wild-type; MT, mutant; HEX, hexachlorofluorescein; CY3.5, cyanine 3.5; CY5,  
 496 cyanine 5; FAM, 5(6)-carboxyfluorescein; BHQ, Black hole quencher

497 <sup>a</sup> Included as an internal amplification control for samples without the del69-70 mutation

498

499  
500

**Table 2.** Interpretation and Reporting of the Two-Reaction Multiplex Genotyping RT-qPCR

Reaction 1 Results				Reaction 2 Results				Action
N501WT (ROX/Cy3.5)	N501Y (FAM)	E484K (CY5)	L452R (HEX)	69_70WT (ROX/Cy3.5)	T478K (FAM)	K417N (CY5)	Del69_70 (HEX)	See Interp Comments <sup>a</sup>
DTD ≤ 40	NDET	NDET	DTD ≤ 40	DTD ≤ 40	DTD ≤ 40	DTD ≤ 40	NDET	Report as 1
DTD ≤ 40	NDET	NDET	DTD ≤ 40	DTD ≤ 40	DTD ≤ 40	NDET	NDET	Report as 1
DTD ≤ 40	NDET	NDET	DTD ≤ 40	NDET	DTD ≤ 40	DTD ≤ 40	NDET	Report as 1
NDET	DTD ≤ 40	DTD ≤ 40	NDET	DTD ≤ 40	NDET	DTD ≤ 40	NDET	Report as 2
NDET	DTD ≤ 40	DTD ≤ 40	NDET	DTD ≤ 40	NDET	NDET	NDET	Report as 3
NDET	DTD ≤ 40	DTD ≤ 40	NDET	NDET	NDET	NDET	DTD ≤ 40	Report as 4
NDET	DTD ≤ 40	NDET	NDET	NDET	NDET	NDET	DTD ≤ 40	Report as 4
NDET	NDET	NDET	NDET	NDET	NDET	DTD ≤ 40	DTD ≤ 40	Report as 5
NDET	NDET	NDET	NDET	NDET	NDET	DTD ≤ 40	NDET	Report as 5
NDET	NDET	NDET	NDET	NDET	NDET	NDET	NDET	Unable (Refer to 6)
<b>Any target with Cq &gt; 40 or abnormal/inconclusive amplification curves.</b>								<b>Review (Refer to 7)</b>
<b>Any scenarios not designated above.</b>								<b>Review (Refer to 7)</b>

<sup>a</sup> **Result Interpretation Comments**

1. Probable Variant of Concern Delta; Increased transmissibility; Decreased susceptibility to BAM\*
2. Possible Variant of Concern Beta versus Variant of Interest Mu; Decreased susceptibility to BAM, ETE, BAM/ETE, CAS, REG\*
3. Possible Variant of Concern Gamma versus Variant of Interest Mu; Decreased susceptibility to BAM, ETE, BAM/ETE, CAS, REG\*
4. Probable Variant of Concern Alpha; Decreased susceptibility to ETE\*
5. Probable Variant of Concern Omicron; Increased transmissibility; Decreased susceptibility to BAM, ETE, BAM/ETE, CAS, IMD, CAS/IMD, CIL, TIX, CIL/TIX, REG; Decreased susceptibility to convalescent plasma
6. Unable to interpret results due to low level of viral RNA
7. **TRIAGE FOR MEDICAL DIRECTOR REVIEW** (Mutations uncommonly seen together, which could indicate possible mixed infection, contamination, or nonspecific amplification. Analyze additional information including previous results, curve shape, etc. Potential new variant or novel mutation in primer/probe sites causing dropout. Consider sequencing if level of viral RNA is sufficient.)

\*Interpretations about mAb susceptibility and plasma susceptibility were based on data from the Stanford Coronavirus Antiviral and Resistance Database ([covdb.stanford.edu](https://covdb.stanford.edu)). Decreased susceptibility to mAb and convalescent plasma defined as >10 fold reduction in neutralization. Monoclonal antibody (mAb) abbreviations: **BAM**: Bamlanivimab/LY-CoV555, **CAS**: Casirivimab/REGN10933, **IMD**: Imdevimab/REGN10987, **CAS/IMD**: Casirivimab+imdevimab/REGN-COV2, **ETE**: Etesevimab/LY-CoV016/JS016/CB6, **CIL**: Cilgavimab/COV2-2130/AZD1061, **TIX**: Tixagevimab/COV2-2196/AZD8895, **TIX/CIL**: Tixagevimab+Cilgavimab, **BAM/ETE**: Bamlanivimab+Etesevimab, **SOT**: Sotrovimab/Vir-7831/S309, **REG**: Regdanvimab/CT-P59.

501  
502

503 **Table 3.** Comparison of RT-qPCR and WGS Results for SARS-CoV-2 Spike Gene Mutation Detection in  
 504 the Initial Cohort (n=502)  
 505

Spike Mutations		WGS pos	WGS neg	PPA (95% CI)	NPA (95% CI)
<b>Del69-70</b>	RT-qPCR pos	43	0	100% (92-100%)	100% (99-100%)
	RT-qPCR neg	0	459		
<b>K417N</b>	RT-qPCR pos	27	0	96% (82-100%)	100% (99-100%)
	RT-qPCR neg	1 <sup>a</sup>	474		
<b>L452R</b>	RT-qPCR pos	403	5 <sup>b</sup>	100% (99-100%)	95% (89-98%)
	RT-qPCR neg	0	94		
<b>T478K</b>	RT-qPCR pos	379	0	100% (99-100%)	100% (97-100%)
	RT-qPCR neg	0	123		
<b>E484K</b>	RT-qPCR pos	35	3 <sup>c</sup>	100% (90-100%)	99% (98-100%)
	RT-qPCR neg	0	464		
<b>N501Y</b>	RT-qPCR pos	70	0	100% (95-100%)	100% (99-100%)
	RT-qPCR neg	0	432		

RT-qPCR, reverse transcription quantitative polymerase chain reaction; WGS, whole-genome sequencing; PPA, positive percent agreement; NPA, negative percent agreement; CI, confidence interval

<sup>a</sup> False negative RT-qPCR result due to synonymous mutation in spike gene amino acid position 418 (codon ATT -> ATC) causing probe dropout.

<sup>b</sup> False negative WGS results due to insufficient read count (<12) at this codon. Manual review of sequences revealed 3-9 mutant reads in each sample.

<sup>c</sup> These three samples were found on WGS to be positive for E484Q. While positive for the E484K target on RT-qPCR, these samples had a distinct blunted amplification curve associated with E484Q as previously described (31).

506



507 **Table 4.** Comparison of RT-qPCR and WGS for SARS-CoV-2 Variant of Concern Detection (n=732)  
508

WHO VOC	WGS	RT-qPCR						All
	PANGO lineage	Alpha	Beta	Gamma	Delta	Omicron	Not a VOC	
Alpha	All Alpha	43	-	-	-	-	-	43
	B.1.1.7	37	-	-	-	-	-	37
	Q.3	6	-	-	-	-	-	6
Beta	Beta	-	2	-	-	-	-	2
	B.1.351	-	2	-	-	-	-	2
Gamma	All Gamma	-	-	20	-	-	-	20
	P.1	-	-	13	-	-	-	13
	P.1.10	-	-	5	-	-	-	5
	P.1.17	-	-	2	-	-	-	2
Delta	All Delta	-	-	-	378	-	-	378
	B.1.617.2	-	-	-	29	-	-	29
	AY.1	-	-	-	20	-	-	20
	AY.2	-	-	-	5	-	-	5
	AY.3	-	-	-	5	-	-	5
	AY.4	-	-	-	1	-	-	1
	AY.13	-	-	-	32	-	-	32
	AY.14	-	-	-	59	-	-	59
	AY.19	-	-	-	1	-	-	1
	AY.20	-	-	-	5	-	-	5
	AY.23	-	-	-	1	-	-	1
	AY.25	-	-	-	7	-	-	7
	AY.25.1	-	-	-	25	-	-	25
	AY.26	-	-	-	15	-	-	15
	AY.35	-	-	-	2	-	-	2
	AY.43	-	-	-	2	-	-	2
	AY.44	-	-	-	77	-	-	77
	AY.46.2	-	-	-	1	-	-	1
	AY.47	-	-	-	8	-	-	8
	AY.48	-	-	-	1	-	-	1
	AY.52	-	-	-	1	-	-	1
	AY.54	-	-	-	3	-	-	3
	AY.59	-	-	-	1	-	-	1
	AY.62	-	-	-	1	-	-	1
	AY.67	-	-	-	3	-	-	3
	AY.74	-	-	-	1	-	-	1
	AY.75	-	-	-	10	-	-	10
	AY.98.1	-	-	-	1	-	-	1
	AY.100	-	-	-	3	-	-	3
	AY.103	-	-	-	26	-	-	26
	AY.110	-	-	-	9	-	-	9
	AY.114	-	-	-	1	-	-	1
AY.116.1	-	-	-	2	-	-	2	
AY.118	-	-	-	5	-	-	5	
AY.119	-	-	-	4	-	-	4	
AY.120.1	-	-	-	1	-	-	1	
AY.121	-	-	-	3	-	-	3	
AY.122	-	-	-	5	-	-	5	
AY.126	-	-	-	2	-	-	2	
Omicron	All Omicron	-	-	-	-	230	-	230
	B.1.1.529/BA.1	-	-	-	-	123	-	123
	BA.1.1	-	-	-	-	107	-	107






	All Non- VOC	-	1	4	-	-	54	59
	A.2.5	-	-	-	-	-	6	6
	B.1	-	-	-	-	-	3	3
	B.1.1.318	-	-	-	-	-	1	1
	B.1.1.519	-	-	-	-	-	1	1
	B.1.311	-	-	-	-	-	1	1
<b>Not a VOC</b>	B.1.427	-	-	-	-	-	3	3
	B.1.429	-	-	-	-	-	8	8
	B.1.526	-	-	-	-	-	10	10
	B.1.621 <sup>a</sup>	-	1	2	-	-	-	3
	BB.2 <sup>a</sup>	-	-	2	-	-	-	2
	B.1.627	-	-	-	-	-	1	1
	B.1.637	-	-	-	-	-	11	11
	XB	-	-	-	-	-	9	9
<b>All</b>	All Variants	43	3	24	378	230	54	732

WGS, whole-genome sequencing; RT-qPCR, reverse transcription quantitative polymerase chain reaction; WHO, World Health Organization; VOC, variant of concern

<sup>a</sup> Variant of interest Mu with E484K and N501Y mutations, and a subset with K417N, which overlaps with VOCs Beta and Gamma

509

	Spike Protein Amino Acid Position					
WHO VOC	69-70	K417	L452	T478	E484	N501
Alpha	deletion	K	L	T	E	Y
Beta*	WT	N	L	T	K	Y
Gamma**	WT	T	L	T	K	Y
Delta	WT	K	R	K	E	N
Omicron	deletion	N	L	K	A	Y

-  Mutation is predicted to be detected & is empirically detected in this variant
-  Mutation is predicted to be not detected & is empirically not detected in this variant
-  Mutation is predicted to be not detected but can be empirically detected in this variant
-  Mutation is not targeted by this assay & is empirically not detected in this variant
-  Wild type residue

